Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Nature Communications|March 24, 2023
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolatesRyuta Uraki, Shun Iida, Peter J Halfmann, et al.Plos Pathogens|August 12, 2010
Biological and structural characterization of a host-adapting amino acid in influenza virusShinya Yamada, Masato Hatta, Bart L Staker, et al.Cell Host & Microbe|December 4, 2014
Influenza virus-host interactome screen as a platform for antiviral drug developmentTokiko Watanabe, Eiryo Kawakami, Jason E Shoemaker, et al.Elife|September 25, 2024
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United StatesAmanda C Perofsky, John Huddleston, Chelsea L Hansen, et al.Med (New York, N.Y.)|March 9, 2022
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variantsSho Miyamoto, Takeshi Arashiro, Yu Adachi, et al.Frontiers in Immunology|March 17, 2023
An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP studyJoanna Waldock, Carol D Weiss, Wei Wang, et al.Cell Host & Microbe|October 24, 2017
A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory DropletsMasaki Imai, Tokiko Watanabe, Maki Kiso, et al.Nature Microbiology|August 31, 2016
Selection of antigenically advanced variants of seasonal influenza virusesChengjun Li, Masato Hatta, David F Burke, et al.Journal of Virology|September 23, 2011
Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaquesTokiko Watanabe, Kyoko Shinya, Shinji Watanabe, et al.Research Square|March 2, 2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2Yoshihiro Kawaoka, Ryuta Uraki, Maki Kiso, et al.Pageof 21